【导读】下周2只新股可申购，恒运昌是半导体设备核心零部件供应商 爱舍伦是医用敷料领域头部企业 爱舍伦的申购代码是920050，发行价为15.98元/股，发行市盈率为14.99倍，参考行业市盈率为29.79倍。 爱舍伦此次总发行数量为1692万股，网上发行数量为1523万股。投资者参与网上申购爱舍伦，申购数量上限为76.13万股。 A股打新投资者注意啦！ 根据目前发行安排，下周有2只新股可申购，分别是北交所新股爱舍伦、上交所科创板新股恒运昌，具体申购时间分别是1月12日、1月16日。 爱舍伦作为一家医用敷料生产商，主要从事应用在专业康复护理与医疗防护领域的一次性医用耗材研发、生产和销售，通过ODM（原始设计制 造商）/OEM（原始设备制造商）等方式为国际知名医疗器械品牌厂商提供相关产品。 近年来，爱舍伦的重要客户包含Medline集团、Zarys International Group、Sejong Healthcare Co., Ltd.、苏州鼎康进出口有限公司、San Pablo Commercial Corp.等。 2022年至2024年及2025年上半年，爱舍伦的营业收入分别为5.74亿元、5.75亿元 ...

【导读】下周2只新股可申购， 恒运昌是半导体设备核心零部件供应商 中国基金报记者 闻言 A股打新投资者注意啦！ 根据目前发行安排，下周有2只新股可申购 ，分别是北交所新股爱舍伦、上交所科创板新股恒运昌，具体申购时间分别是 1月12日 、 1月 16日 。 爱舍伦 是 医用敷料 领域头部企业 爱舍伦的申购代码是920050，发行价为15.98元/股，发行市盈率为14.99倍，参考行业市盈率为29.79倍。 爱舍伦此次总发行数量为1692万股，网上发行数量为1523万股。投资者参与网上申购爱舍伦，申购数量上限为76.13万股。 爱舍伦 作为一家医用敷料生产商， 主要从事应用在专业康复护理与医疗防护领域的一次性医用耗材研发、生产和销售，通过ODM （原始 设计制造商） /OEM （原始设备制造商） 等方式为国际知名医疗器械品牌厂商提供相关产品。 近年来，爱舍伦的重要客户包含 Medline集团 、 Zarys International Group 、 Sejong Healthcare Co., Ltd. 、 苏州鼎康进出口有限公 司 、 San Pablo Commercial Corp. 等。 | | | | ...

相关研究 证券分析师 刘靖 A0230512070005 liujing@swsresearch.com 王雨晴 A0230522010003 wanqyg@swsresearch.com 联系人 2026年01月09日 爰舍伦 (920050) : 国内医用敷料行 业头部企业,积极扩充产能 -北交所新股申购策略报告之一百五十五 请务必仔细阅读正文之后的各项信息披露与声明 基本面：国内医用敷料行业头部企业。公司 2015年成立，总部位于江苏苏州，主要从事 低值医用耗材的研发、生产及销售,通过 ODM/OEM 等方式为国际知名医疗器械品牌 厂商提供相关产品。根据中国医药保健品进出口商会 2024 年 9 月 20 日出具的《关于 江苏爱舍伦医疗科技集团股份公司在医用敷料行业地位的说明》，2021 年、2022 年、 2023 年、2024 年 1-6 月江苏爱舍伦医疗科技集团股份有限公司医用敷料出口金额（铺 垫类敷料）排名全国前十。贯彻核心客户战略，合作规模持续扩大。核心客户 Medline 集团、Zarys International Group、Sejong Healthcare co., Ltd 均为国际 ...

近一年中国医用敷料出口情况统计图 相关报告：智研咨询发布的《2026-2032年中国医用敷料行业市场竞争态势及发展趋向分析报告》 根据中国海关数据显示：2025年11月中国医用敷料出口数量为2.68万吨，同比增长8.7%，出口金额为2 亿美元，同比增长1.4%。 数据来源：中国海关，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 ...

Group 1 - The core point of the article is that Zhend Medical (SH 603301) held its fourth fifth board meeting on December 15, 2025, to discuss the proposal for the 2026 first extraordinary shareholders' meeting [1] - Zhend Medical's revenue composition for the first half of 2025 was entirely from medical dressings, accounting for 100.0% [2] - As of the report, Zhend Medical's market capitalization was 17.6 billion yuan [2] Group 2 - The article mentions a controversy surrounding a product called "Tongyan Needle," which reportedly generated 300 million yuan in annual sales, with concerns raised about the legitimacy of several related parties [2] - There are allegations that the Qian siblings have nearly "emptied" Jiangsu Wuzhong, leading to the company's impending delisting [2]

数据来源：中国海关，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 相关报告：智研咨询发布的《2026-2032年中国医用敷料行业市场竞争态势及发展趋向分析报告》 根据中国海关数据显示：2025年10月中国医用敷料出口数量为2.32万吨，同比下降10.2%，出口金额为 1.77亿美元，同比下降11.8%。 近一年中国医用敷料出口情况统计图 ...

Core Viewpoint - The company, Steady Medical, is facing challenges in market valuation despite strong performance metrics, with a current market capitalization of approximately 24 billion, significantly lower than peers in the industry [2][3]. Group 1: Company Performance - As of November 18, 2025, Steady Medical's stock closed at 41.31 yuan, down 0.86%, with a trading volume of 39,000 shares and a turnover of 161 million yuan [1]. - The company has consistently focused on enhancing operational performance and shareholder value, with its product and brand strength gaining wider market recognition [2][3]. Group 2: Market Sentiment and Investor Relations - The company acknowledges the impact of macroeconomic factors, industry policies, and market sentiment on its stock price, which has been under pressure despite strong earnings growth [2][3]. - The company has established a professional team for investor relations and is committed to improving market recognition and trust [2]. Group 3: Future Strategies and Investments - Steady Medical plans to invest 2 billion yuan in a new non-woven fabric production base, aiming to enhance supply chain security and develop new products, while managing investment risks through dynamic capacity planning [3]. - The company is implementing a new equity incentive plan for 2024, setting ambitious revenue targets for 2025-2027 to drive growth and improve operational efficiency [2][3].

Core Viewpoint - The company, Steady Medical (300888), has experienced a significant decline in market value despite having strong performance metrics compared to its peers in the medical dressing industry [1] Group 1: Company Performance - Steady Medical is recognized for having the best performance and the strongest growth rate among its peers, with earnings per share equaling the combined total of its competitors, ZhenDe and Aomei [1] - The company has been focusing on enhancing operational performance and shareholder value, leading to increased product and brand recognition in the market [1] Group 2: Market Conditions - The company's stock price is influenced by multiple factors, including macroeconomic conditions, industry policies, and market sentiment [1] - Despite the challenges in market valuation, the company maintains a positive outlook on its future prospects due to strengthened core competitiveness [1]

Group 1 - The core point of the article highlights the recent decline in the stock price of Zhendemedical, which fell by 5.16% to 76.02 yuan per share, with a trading volume of 398 million yuan and a turnover rate of 1.91%, resulting in a total market capitalization of 20.256 billion yuan [1] - Zhendemedical, established on August 18, 1994, and listed on April 12, 2018, specializes in the production, research, and sales of medical dressings. The main revenue composition includes: surgical infection control 43.04%, basic care 20.46%, ostomy and modern wound care 18.59%, pressure treatment and fixation 10.75%, infection control protection 6.58%, and others 0.58% [1] Group 2 - From the perspective of major fund holdings, data shows that one fund under Jiashi Fund has a significant position in Zhendemedical. Jiashi New Tanghui Regular Mixed A (005088) held 10,200 shares in the third quarter, accounting for 1.03% of the fund's net value, making it the third-largest holding. The estimated floating loss today is approximately 42,200 yuan [2] - Jiashi New Tanghui Regular Mixed A (005088) was established on September 28, 2017, with a latest scale of 45.2371 million yuan. Year-to-date return is 14.94%, ranking 5064 out of 8140 in its category; the one-year return is 10.12%, ranking 5745 out of 8057; and since inception, it has incurred a loss of 5.7% [2]

Core Viewpoint - Aomei Medical (002950) has transitioned from "manufacturing" to "quality manufacturing" and then to "intelligent manufacturing," enhancing its competitive advantage through technological integration [1] Group 1: Company Development - Aomei Medical is recognized as a global leader in the production of medical dressings and infection protection products [1] - The company has implemented multiple technological upgrades in recent years to improve production efficiency [1] Group 2: Product Innovation - Aomei Medical has continuously launched functional dressing products and medical care pads, receiving positive feedback from patients and consumers [1] - The company aims to deepen its focus on product manufacturing and development to strengthen its market competitiveness [1]